517O Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial

Paul DiSilvestro, K.N. Moore, Charlie Gourley et al.|Annals of Oncology|2022

Cited by 6